Romain Hardet
Rouen, 76000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 02, 2025
Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 02, 2025
Modifying immune responses to adeno-associated virus vectors by capsid engineering.
Journal: Molecular therapy. Methods & clinical development
Published: January 16, 2023
Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy.
Journal: Molecular therapy. Methods & clinical development
Published: October 18, 2022
Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo.
Journal: Frontiers in immunology
Published: August 05, 2022
Development of Antibody and Nanobody Tools for P2X7.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 01, 2022
Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 13, 2020
Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano).
Journal: Frontiers in oncology
Published: January 12, 2020
Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle.
Journal: Molecular therapy. Methods & clinical development
Published: August 23, 2019
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.
Journal: The Journal of clinical investigation
Published: May 21, 2018
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Journal: Nature communications
Published: March 10, 2018
Last Updated: 09/26/2026